The addition of ustekinumab, an IL-12 and IL-23 inhibitor, to standard-of-care treatment was more efficacious than placebo in the treatment of patients with active systemic lupus erythematosus (SLE) in a double-blind phase II randomized controlled trial. More patients in the ustekinumab group achieved an SLE responder index-4 (SRI-4) response at week 24 than in the placebo group (37 (62%) versus 14 (33%); P = 0.006). The safety profile of ustekinumab was consistent with that reported in previous trials of ustekinumab for other diseases.
References
Original article
van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. https://doi.org/10.1016/S0140-6736(18)32167-6 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
McHugh, J. Ustekinumab — a novel treatment?. Nat Rev Rheumatol 14, 622 (2018). https://doi.org/10.1038/s41584-018-0105-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0105-6
